BioAtla (BCAB) EBITDA Margin (2020 - 2025)

BioAtla's EBITDA Margin history runs 4 years deep, the most recent figure standing at 462.75% for Q4 2025.

• On a quarterly basis, EBITDA Margin changed N/A year-over-year to 462.75% in Q4 2025; TTM through Dec 2025 was 456.19%, a 21602.0% increase from a year earlier, with the FY2025 full-year figure at 2965.25%, down 229304.0% from the prior year.
• EBITDA Margin eased to 462.75% in Q4 2025 per BCAB's latest filing, from 102.45% in the prior quarter.
• Across five years, EBITDA Margin topped out at 102.45% in Q3 2024 and bottomed at 12184.0% in Q2 2021.
• The 3-year median for EBITDA Margin is 462.75% (2025), against an average of 4249.73%.
• Biggest YoY gain for EBITDA Margin was 980505 bps in 2021; the steepest drop was 980505 bps in 2021.
• Year by year, EBITDA Margin stood at 12184.0% in 2021, then jumped by 99 bps to 102.45% in 2024, then slumped by 352 bps to 462.75% in 2025.
• Per Business Quant, the three latest BCAB EBITDA Margin figures stand at 462.75% (Q4 2025), 102.45% (Q3 2024), and 12184.0% (Q2 2021).